Last reviewed · How we verify

Estring (Estradiol)

Pfizer Inc. · FDA-approved approved Small molecule Verified Quality 71/100

Prevents pregnancy primarily by suppressing ovulation.

Iclevia is a combination oral contraceptive containing levonorgestrel and ethinyl estradiol indicated for pregnancy prevention in females of reproductive potential. The drug works primarily by suppressing ovulation through hormonal mechanisms. Significant contraindications exist for patients with thrombotic disease risk, cardiovascular disease, uncontrolled hypertension, certain migraine types, and hormone-sensitive cancers. Metabolic enzyme inducers may reduce contraceptive effectiveness, requiring backup contraception methods.

At a glance

Generic nameEstradiol
SponsorPfizer Inc.
Drug classCombined Oral Contraceptive (COC)
TargetOvulation
ModalitySmall molecule
Therapeutic areaOncology
PhaseFDA-approved

Mechanism of action

Iclevia is a combination oral contraceptive containing levonorgestrel (a progestin) and ethinyl estradiol (an estrogen). The primary mechanism of action is suppression of ovulation, preventing the release of an egg from the ovary. The hormonal components work together to inhibit the luteinizing hormone (LH) surge necessary for ovulation to occur.

Approved indications

Boxed warnings

Common side effects

Drug interactions

Patents

PatentExpiryType
97309002028-07-10Method of Use
102586302032-11-21Method of Use
103987082032-11-21Method of Use
104710722032-11-21Method of Use
105375812032-11-21Formulation
112468752032-11-21Method of Use
112414452032-11-21Method of Use
112666612034-02-02Method of Use

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA Orange BookPatents + exclusivity

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: